- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04686045
Stroke Prevention in Atrial Fibrillation Patients Between 2004 and 2020
Prevention of thromboembolic complications is an important part in the management of patients with atrial fibrillation (AF). European and American guidelines recommend the use of non-vitamin K antagonist oral anticoagulants (NOACs) over therapy with vitamin K antagonists (VKA) in most AF patients. The number of patients treated with NOACs has increased significantly during the last few years. In the primary randomized controlled trials leading to their approval, compared to warfarin, NOACs were shown to be either noninferior or superior for stroke prevention in AF, with similar or reduced rates of bleeding, especially intracranial haemorrhage.
The aim of this study was to assess the frequency of oral anticoagulants using, espescially apixaban, dabigatran, and rivaroxaban, and the predictors of their prescription in a group of hospitalised patients with AF.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Kielce, Poland, 25-525
- Recruiting
- Iwona Gorczyca
-
Contact:
- Iwona Gorczyca, MD,PhD
- Phone Number: +48 604 40 79 56
- Email: iwona.gorczyca@interia.pl
-
Contact:
- Olga Jelonek, MD
- Email: olga_jelonek@wp.pl
-
-
Grunwaldzka 45
-
Kielce, Grunwaldzka 45, Poland, 25-637
- Recruiting
- 1st Clinic of Cardiology and Electotherapy
-
Contact:
- Iwona Gorczyca, MD, PhD
- Phone Number: +48 604407956
- Email: iwona.gorczyca@interia.pl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- non-valvular atrial fibrillation
Exclusion Criteria:
- valvular atrial fibrillation
- death during hospitalization
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
oral anticoagulant treatment
Time Frame: one year
|
one year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- The Jan Kochanowski Uniwersity
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation; Stroke Prevention
-
AstraZenecaTerminatedStroke Prevention in Patients With Atrial FibrillationSweden, Norway, Poland, United Kingdom, Finland, Denmark, United States, Czech Republic, Belgium
-
BayerJanssen, LPCompletedAtrial Fibrillation (Prevention of Stroke)Germany
-
University of LeipzigUnknownAtrial Fibrillation | Left Atrial Appendage | Stroke Prevention
-
Rigshospitalet, DenmarkAbbott; FeopsUnknownAtrial Fibrillation | Stroke PreventionDenmark, Spain, Sweden, Belgium, Canada, France, Italy
-
Central Clinical Hospital of the Ministry of Internal...RecruitingAtrial Fibrillation | Safety Issues | Stroke PreventionPoland
-
Region Örebro CountyUniversity Hospital, Linkoeping; Danderyd HospitalCompletedStroke | Postoperative Atrial Fibrillation | Oral Anticoagulation | Post PCI Atrial FibrillationSweden
-
Anthos Therapeutics, Inc.Laboratory Corporation of America; The TIMI Study GroupActive, not recruitingStroke | Atrial Fibrillation (AF)United States, Canada, Czechia, Hungary, Korea, Republic of, Poland, Taiwan
-
University of SurreyRoyal Surrey County Hospital NHS Foundation Trust; Ashford and St. Peter's...WithdrawnStroke | Paroxysmal Atrial FibrillationUnited Kingdom
-
Hospital Universitari Vall d'Hebron Research InstituteRecruitingParoxysmal Atrial Fibrillation | Cryptogenic StrokeSpain
-
Lifetech Scientific (Shenzhen) Co., Ltd.RecruitingNon-valvular Atrial Fibrillation | Embolic StrokeChina
Clinical Trials on observational study
-
Taysha Gene Therapies, Inc.Withdrawn
-
AstraZenecaRecruitingNon-Small Cell Lung CancerUnited States
-
University of ManitobaCompletedObesity | Pregnancy | Cesarean SectionCanada
-
University of Castilla-La ManchaRecruitingKnee OsteoarthritisSpain
-
AstraZenecaRecruiting
-
Drexel UniversityCompletedOsteoporosisUnited States
-
The Aurum Institute NPCKarolinska Institutet; Ludwig-Maximilians - University of Munich; University... and other collaboratorsUnknownRespiratory Tract Infections | Tuberculosis, PulmonaryMozambique, South Africa, Tanzania, Gambia
-
Oslo University HospitalThe Research Council of NorwayRecruitingMesothelioma | Pseudomyxoma Peritonei | Colorectal Carcinoma | Ovarian CarcinomaNorway
-
Oslo University HospitalThe Research Council of NorwayActive, not recruiting
-
University Hospital, AntwerpUniversiteit AntwerpenUnknownType 1 Diabetes | Diastolic Dysfunction | Coronary Artery CalcificationsBelgium